Doxycycline as a potential partner of COVID-19 therapies

Alexandre E Malek; Bruno P Granwehr; Dimitrios P Kontoyiannis

doi:10.1016/j.idcr.2020.e00864

Doxycycline as a potential partner of COVID-19 therapies

IDCases. 2020 Jun 6:21:e00864. doi: 10.1016/j.idcr.2020.e00864. eCollection 2020.

Authors

Alexandre E Malek¹, Bruno P Granwehr¹, Dimitrios P Kontoyiannis¹

Affiliation

¹ Department of Infectious Diseases, Infection Control and Employee Health, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Abstract

Coronavirus disease 2019 (COVID-19) is a major public health challenge, and the current antiviral arsenal for treatment is limited, with questionable efficacy. Major efforts are under way for discovery of new effective agents, but the validation of new potential treatments for COVID-19 may take a long time. Therefore, the repurposing of existing drugs for new indications is needed. In this article, we argue for the potential benefits of using doxycycline with either hydroxycholoroquine or other putative agents for COVID-19 treatment, as doxycycline has antiviral and anti-inflammatory activities by dampening the cytokine storm and to prevent lung damage.

Keywords: 2019 novel coronavirus; COVID-19; Doxycycline; Hydroxychloroquine; Remdesivir.

Publication types

Editorial